CD28-mediated co-stimulation: a quantitative support for TCR signalling.
The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Under physiological conditions CD28-derived signals alone are not capable of inducing T cell activation, whereas simultaneous engagement of the TCR and CD28 (e.g. by its natural ligands CD80 and CD86 which are expressed on mature antigen presenting cells) leads to activation of resting T lymphocytes (reviewed in [3], [4]).”
From Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies (2008) · cites this paper as [3]
In the citing paper
“Under physiological conditions CD28-derived signals alone are not capable of inducing T cell activation, whereas simultaneous engagement of the TCR and CD28 (e.g. by its natural ligands CD80 and CD86 which are expressed on mature antigen presenting cells) leads to activation of resting T lymphocytes (reviewed in [3], [4]).”
From Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies (2008) · cites this paper as [3]
In the citing paper
“In mouse and human T cells the dimeric transmembrane glycoprotein CD28 represents the most important co-stimulatory molecule.”
From Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies (2008) · cites this paper as [3]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
CD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717 · cited 6×
“This phosphorylation requires PtdIns(3,4,5)P 3 -activated AKT kinase and it is sensitive to inhibition by pharma cological inhibitors of PI3K(25,45).”
BackgroundInfluentialTOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712 · cited 7×
“This phosphorylation requires PtdIns(3,4,5)P 3 -activated AKT kinase and it is sensitive to inhibition by pharma cological inhibitors of PI3K(25,45).”
BackgroundInfluentialThe lineage decisions of helper T cells
Murphy, K. M., & Reiner, S. L. (2002) · Nature Reviews Immunology · doi:10.1038/nri954 · Cited by 1,674
Schwartz, R. H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141110 · Cited by 1,487
The CD28 Signaling Pathway Regulates Glucose Metabolism
Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., Elstrom, R. L., June, C. H., & Thompson, C. B. (2002) · Immunity · doi:10.1016/s1074-7613(02)00323-0 · Cited by 1,475 · cited 1×
“CD28-induced activation of AKT upregulates glucose metabolis”
Differential T Cell Costimulatory Requirements in CD28-Deficient Mice
Shahinian, A., Pfeffer, K., Lee, K. P., Kündig, T. M., Kishihara, K., Wakeham, A., Kawai, K., Ohashi, P. S., Thompson, C. B., & Mak, T. W. (1993) · Science · doi:10.1126/science.7688139 · Cited by 1,257 · cited 7×
“This phosphorylation requires PtdIns(3,4,5)P 3 -activated AKT kinase and it is sensitive to inhibition by pharma cological inhibitors of PI3K(25,45).”
BackgroundInfluentialCD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., & Thompson, C. B. (1995) · Immunity · doi:10.1016/1074-7613(95)90161-2 · Cited by 1,210
T Cell Activation Determined by T Cell Receptor Number and Tunable Thresholds
Viola, A., & Lanzavecchia, A. (1996) · Science · doi:10.1126/science.273.5271.104 · Cited by 1,023 · cited 1×
“This is also indicated by studies showing that CD28 ligation lowers the number of triggered TCRs that are required for a given respons”
Background
Cited by
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
NFAT proteins: key regulators of T-cell development and function
Macian, F. (2005) · Nature Reviews Immunology · doi:10.1038/nri1632 · Cited by 1,569
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898
“The importance of cell intrinsic regulation has come from studies showing that coligation of the coreceptor with TCR can induce anergy (21, 22) and, secondly, that transgenic expression of CTLA-4 lacking the cytoplasmic domain on a Ctla4 ⁄ ) background does not restore a normal phenotype as observed with flCTLA-4 (107…”
BackgroundAdoptive immunotherapy for cancer: building on success
Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1842 · Cited by 845
Molecular Mechanisms of Treg-Mediated T Cell Suppression
Schmidt, A., Oberle, N., & Krammer, P. H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00051 · Cited by 761
“IS CD28 SIGNALING AFFECTED IN Tcons UPON SUPPRESSION BY Tregs? Proliferation and activation of T cells does not only require TCR stimulation but also a second, costimulatory signal (Acuto and Michel, 2003).”
BackgroundA Fundamental Role for Interleukin-21 in the Generation of T Follicular Helper Cells
Vogelzang, A., McGuire, H. M., Yu, D., Sprent, J., Mackay, C. R., & King, C. (2008) · Immunity · doi:10.1016/j.immuni.2008.06.001 · Cited by 739
T Follicular Helper (TFH) Cells in Normal and Dysregulated Immune Responses
King, C., Tangye, S. G., & Mackay, C. R. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090344 · Cited by 632
“Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5–positive CD4 cells and germinal centers.”
BackgroundInfluentialImmunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
The significance of OX40 and OX40L to T‐cell biology and immune disease
Croft, M., So, T., Duan, W., & Soroosh, P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00766.x · Cited by 604
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
Zhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017) · Biomarker Research · doi:10.1186/s40364-017-0102-y · Cited by 578
The pharmacology of second-generation chimeric antigen receptors
van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 555
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
Feucht, J., Sun, J., Eyquem, J., Ho, Y.-J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., & Sadelain, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0290-5 · Cited by 547
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 507
“The CTLA-4 co-inhibitory receptor is found on lately induced T cells and interacts with the identical ligands as CD28 but with higher affinity [9, 10].”
BackgroundMetabolic pathways in T cell activation and lineage differentiation
Almeida, L., Lochner, M., Berod, L., & Sparwasser, T. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.10.009 · Cited by 475
Teaching an old dog new tricks: next-generation CAR T cells
Tokarew, N., Ogonek, J., Endres, S., von Bergwelt-Baildon, M., & Kobold, S. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0325-1 · Cited by 440
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Okkenhaug, K. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095946 · Cited by 446
“Rather, CD28 may act to boost and sustain signaling by the TCR more generally (214, 215).”
CD28 extinction in human T cells: altered functions and the program of T‐cell senescence
Vallejo, A. N. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00256.x · Cited by 431
“In the context of autoimmune and inflammatory diseases however, restoration of CD28 expression may or may not be beneficial due to the potency of the CD28 costimulatory signal (3, 4) that Minimal promoter”
BackgroundB7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse
Pentcheva-Hoang, T., Egen, J. G., Wojnoonski, K., & Allison, J. P. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.017 · Cited by 436
“This the mRNA stability of interleukin-2 (IL-2), as well as by accumulation defect was alleviated by the presence of upregulating the antiapoptotic protein Bcl-X L (reviewed endogenous wt CD28 and was exacerbated by high in Acuto and Michel, 2003).”
BackgroundCARMA1, BCL-10 and MALT1 in lymphocyte development and activation
Thome, M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1352 · Cited by 391
COOPERATION BETWEEN CD4+AND CD8+T CELLS: When, Where, and How
Castellino, F., & Germain, R. N. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115825 · Cited by 376
Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors
Andrejeva, G., & Rathmell, J. C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.004 · Cited by 373
“Costimulatory signals, such as CD28, then activate a cascade of proliferative and biosynthetic programs that are further modulated by the cytokine milieu in the microenvironment (Acuto and Michel, 2003).”
BackgroundCTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 402
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation
Riley, J. L., & June, C. H. (2005) · Blood · doi:10.1182/blood-2004-04-1596 · Cited by 315
Yokosuka, T., Kobayashi, W., Sakata-Sogawa, K., Takamatsu, M., Hashimoto-Tane, A., Dustin, M. L., Tokunaga, M., & Saito, T. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.011 · Cited by 309
“CD28, which is constitutively expressed on both naive and effector T cells, plays a predominant role in costimulation by binding its ligands, CD80 (B7-1) and CD86 (B7-2) (Acuto and Michel, 2003; Chambers et al., 2001; Rudd and Schneider, 2003; Sharpe and Freeman, 2002).”
BackgroundCD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86
Orabona, C., Grohmann, U., Belladonna, M. L., Fallarino, F., Vacca, C., Bianchi, R., Bozza, S., Volpi, C., Salomon, B. L., Fioretti, M. C., et al. (2004) · Nature Immunology · doi:10.1038/ni1124 · Cited by 302
Molecular and nanoengineering approaches towards activatable cancer immunotherapy
Zhang, C., & Pu, K. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00773c · Cited by 302
Powell, D. J., Dudley, M. E., Robbins, P. F., & Rosenberg, S. A. (2005) · Blood · doi:10.1182/blood-2004-06-2482 · Cited by 293
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 270
“The CTLA-4 co-inhibitory receptor is largely demonstrated on lately activated T cells and creates interfaces with the same ligands as CD28 but with higher affinity [43, 44].”
BackgroundGenomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2
Ungewickell, A., Bhaduri, A., Rios, E., Reuter, J., Lee, C. S., Mah, A., Zehnder, A., Ohgami, R., Kulkarni, S., Armstrong, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3370 · Cited by 277
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors
Thompson, E. D., Enriquez, H. L., Fu, Y.-X., & Engelhard, V. H. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092454 · Cited by 249
“, 1993) can proceed in mice deficient in CD28, suggesting that high TCR occupancy can provide the signal amplification normally provided through CD28 co-stimulation (Acuto and Michel, 2003).”
BackgroundMolecular and Cellular Functions of CTLA-4
Van Coillie, S., Wiernicki, B., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_2 · Cited by 243
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer
Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A., Fridman, W. H., Sautès-Fridman, C., Ma, Y., Tartour, E., Zitvogel, L., et al. (2012) · OncoImmunology · doi:10.4161/onci.22009 · Cited by 235
Condensation of the plasma membrane at the site of T lymphocyte activation
Gaus, K., Chklovskaia, E., Fazekas de St. Groth, B., Jessup, W., & Harder, T. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505047 · Cited by 251
“Full activation of primary resting T lymphocytes requires the engagement of costimulatory receptors in addition to the TCR and, most prominently, the engagement of CD28 with the B7 antigen receptor (Acuto and Michel, 2003).”
BackgroundZimmerman, A. W., Joosten, B., Torensma, R., Parnes, J. R., van Leeuwen, F. N., & Figdor, C. G. (2006) · Blood · doi:10.1182/blood-2005-09-3881 · Cited by 228
Yokosuka, T., Kobayashi, W., Takamatsu, M., Sakata-Sogawa, K., Zeng, H., Hashimoto-Tane, A., Yagita, H., Tokunaga, M., & Saito, T. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.006 · Cited by 213
Vallejo, A. N., Weyand, C. M., & Goronzy, J. J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.01.002 · Cited by 223
Cyclic AMP-mediated immune regulation — Overview of mechanisms of action in T cells
Mosenden, R., & Taskén, K. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2010.11.018 · Cited by 212
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
Asmamaw Dejenie, T., Tiruneh G/Medhin, M., Dessie Terefe, G., Tadele Admasu, F., Wale Tesega, W., & Chekol Abebe, E. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2114254 · Cited by 187
Role of Microglia in CNS Autoimmunity
Goldmann, T., & Prinz, M. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/208093 · Cited by 196
“For T cell activation by an antigen presenting cell (APC), two signals are prerequisites: first, antigen peptide presentation at the cell surface via major histocompatibility complex (MHC) to the specific T cell receptor [79, 80] and, second, a costimulatory interaction of CD80/86 or CD40 located on APCs with CD28 or…”
Sanmamed, M. F., Pastor, F., Rodriguez, A., Perez-Gracia, J. L., Rodriguez-Ruiz, M. E., Jure-Kunkel, M., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.014 · Cited by 190
TLR2 engagement on CD8 T cells lowers the thresholdfor optimal antigen‐induced T cell activation
Cottalorda, A., Verschelde, C., Marçais, A., Tomkowiak, M., Musette, P., Uematsu, S., Akira, S., Marvel, J., & Bonnefoy‐Berard, N. (2006) · European Journal of Immunology · doi:10.1002/eji.200636181 · Cited by 190
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
Bui, T. A., Mei, H., Sang, R., Ortega, D. G., & Deng, W. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105266 · Cited by 173
“18,19 The third and fourth CAR generations expanded upon the second CAR generation by incorporating additional signalling domains such as 4-1BB or interleukin 12 (IL-12) cytokines.”
Backgroundvan de Ven, K., & Borst, J. (2015) · Immunotherapy · doi:10.2217/imt.15.32 · Cited by 177
Mahgoub, M., Yasunaga, J.-I., Iwami, S., Nakaoka, S., Koizumi, Y., Shimura, K., & Matsuoka, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715724115 · Cited by 177
“In contrast, pathways associated with cell proliferation, such as CD3, CD28, and melanogenesis-associated transcription factor (46, 47), are significantly activated in Tax-negative cells that express HBZ (Fig.”
BackgroundIntroducing Membrane Charge and Membrane Potential to T Cell Signaling
Ma, Y., Poole, K., Goyette, J., & Gaus, K. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01513 · Cited by 167
Crystal structure of a soluble CD28-Fab complex
Evans, E. J., Esnouf, R. M., Manso-Sancho, R., Gilbert, R. J. C., James, J. R., Yu, C., Fennelly, J. A., Vowles, C., Hanke, T., Walse, B., et al. (2005) · Nature Immunology · doi:10.1038/ni1170 · Cited by 180
Engels, N., König, L. M., Heemann, C., Lutz, J., Tsubata, T., Griep, S., Schrader, V., & Wienands, J. (2009) · Nature Immunology · doi:10.1038/ni.1764 · Cited by 177
“The ITT, especially that of mIgG, and its 'downstream' signaling properties are similar to those described for the well known phosphorylation-acceptor site Tyr-Met-Asn-Met of CD28, a costimulatory molecule key for activation of naive but not memory T cell”
BackgroundLim, T. S., Goh, J. K. H., Mortellaro, A., Lim, C. T., Hämmerling, G. J., & Ricciardi-Castagnoli, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045185 · Cited by 168
“Both CD80 and CD86 can bind to the T-cell stimulatory receptor CD28 [30,31,32,33,34], and to the inhibitory receptor CTLA4 [35,36,37].”
InfluentialIn situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
Vanpouille-Box, C., Pilones, K. A., Wennerberg, E., Formenti, S. C., & Demaria, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.105 · Cited by 177
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo
Tian, G., Courtney, A. N., Jena, B., Heczey, A., Liu, D., Marinova, E., Guo, L., Xu, X., Torikai, H., Mo, Q., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83476 · Cited by 173
Coquet, J. M., Ribot, J. C., Bąbała, N., Middendorp, S., van der Horst, G., Xiao, Y., Neves, J. F., Fonseca-Pereira, D., Jacobs, H., Pennington, D. J., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20112061 · Cited by 164
“CD28 amplifies the TCR signal and lowers the threshold for entry into cell cycle (Acuto and Michel, 2003), whereas CD27 provides survival signals throughout successive cell cycles (Hendriks et al.”
BackgroundThe NF-κB-independent functions of IKK subunits in immunity and cancer
Chariot, A. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.05.006 · Cited by 176
The role of oxidative and inflammatory stress and persistent viral infections in immunosenescence
Bauer, M. E., & Fuente, M. D. L. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.01.001 · Cited by 166
Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression
Patil, N. K., Bohannon, J. K., & Sherwood, E. R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.019 · Cited by 161
“Co-stimulatory signals through cell surface CD28, along with T cell receptor (TCR), are required for optimal T cell functions including proliferation, cell survival and production of IFNγ and interleukin-2, which are critical to combat infections [62].”
BackgroundHirano, N., Butler, M. O., Xia, Z., Ansén, S., von Bergwelt-Baildon, M. S., Neuberg, D., Freeman, G. J., & Nadler, L. M. (2006) · Blood · doi:10.1182/blood-2005-05-2073 · Cited by 168
Alnefaie, A., Albogami, S. M., Asiri, Y. A., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.797440 · Cited by 178
“The intracellular domain classifies CARs into five generations: first has a single activation domain, a cytoplasmic domain mostly CD3 zeta (CD3ζ), and some studies used the gamma chain (γ) of the Fc receptors, the second generation has CD3ζ plus one costimulatory domain, obtained from costimulatory molecules such as 4…”
BackgroundKong, K.-F., Yokosuka, T., Canonigo-Balancio, A. J., Isakov, N., Saito, T., & Altman, A. (2011) · Nature Immunology · doi:10.1038/ni.2120 · Cited by 151
“The signaling events associated with CD28 are not entirely understood, and it remains controversial whether CD28 induces unique signals or simply amplifies TCR signals 37,38 .”
Garçon, F., Patton, D. T., Emery, J. L., Hirsch, E., Rottapel, R., Sasaki, T., & Okkenhaug, K. (2008) · Blood · doi:10.1182/blood-2007-08-108050 · Cited by 153
The T-cell-receptor signaling network
Huse, M. (2009) · Journal of Cell Science · doi:10.1242/jcs.042762 · Cited by 183
“enhances TCR signaling quantitatively ( Acuto and Michel, 2003 ).”
BackgroundTGF-β signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer
Pérez, L. G., Kempski, J., McGee, H. M., Pelczar, P., Agalioti, T., Giannou, A. D., Konczalla, L., Brockmann, L., Wahib, R., Xu, H. Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16363-w · Cited by 172
The Immunological Synapse, TCR Microclusters, and T Cell Activation
Yokosuka, T., & Saito, T. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-03858-7_5 · Cited by 149
“For a decade, biochemical analyses have suggested some candidates such as PI3K, protein phosphatase 2A (PP2A), Grb2, Gads, interleukin-2 tyrosine kinase (Itk), Vav, and Akt (Alegre et al. 2001; Acuto and Michel 2003), but most of these molecules function downstream of TCR as well as CD28.”
BackgroundCD4 T-Cell Memory Generation and Maintenance
Gasper, D. J., Tejera, M. M., & Suresh, M. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014010373 · Cited by 173
Modulation of CD28 expression with anti–tumor necrosis factor α therapy in rheumatoid arthritis
Bryl, E., Vallejo, A. N., Matteson, E. L., Witkowski, J. M., Weyand, C. M., & Goronzy, J. J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21353 · Cited by 142
van Gisbergen, K. P. J. M., Klarenbeek, P. L., Kragten, N. A. M., Unger, P. A., Nieuwenhuis, M. B. B., Wensveen, F. M., ten Brinke, A., Tak, P. P., Eldering, E., Nolte, M. A., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.04.020 · Cited by 142
CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism
Engelhardt, J. J., Sullivan, T. J., & Allison, J. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1052 · Cited by 135
“We cannot rule out that CTLA-4 only inhibits a CD28-specific signaling pathway; however, current data do not support the existence of this pathway (48, 49).”
Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.
Glassman, P. M., & Balthasar, J. P. (2014) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.01.002 · Cited by 170
Strategies to enhance T-cell reconstitution in immunocompromised patients
van den Brink, M. R. M., Alpdoğan, Ö., & Boyd, R. L. (2004) · Nature reviews. Immunology · doi:10.1038/nri1484 · Cited by 148
Essential Role for IκB Kinase β in Remodeling Carma1-Bcl10-Malt1 Complexes upon T Cell Activation
Wegener, E., Oeckinghaus, A., Papadopoulou, N., Lavitas, L.-M., Schmidt‐Supprian, M., Ferch, U., Mak, T. W., Ruland, J., Heissmeyer, V., & Krappmann, D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.027 · Cited by 142
Combination of Radiotherapy and Immune Checkpoint Inhibitors
Pilones, K. A., Vanpouille‐Box, C., & Demaria, S. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.004 · Cited by 149
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Le Floc’h, A., Tanaka, Y., Bantilan, N. S., Voisinne, G., Altan-Bonnet, G., Fukui, Y., & Huse, M. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131324 · Cited by 134
“The resulting F-actin ring regulates the trafficking and clustering of signaling complexes and integrins (Varma et al., 2006; Nguyen et al., 2008; Babich et al., 2012; Yi et al., 2012).”
T cell ageing: effects of age on development, survival & function.
Salam, N., Rane, S., Das, R., Faulkner, M. F., Gund, R., Kandpal, U., Lewis, V., Mattoo, H., Prabhu, S. B., Ranganathan, V., et al. (2013) · PubMed Central · Cited by 179
DC-HIL is a negative regulator of T lymphocyte activation
Chung, J.-S., Sato, K., Dougherty, I. I., Cruz, P. D., & Ariizumi, K. (2007) · Blood · doi:10.1182/blood-2006-11-053769 · Cited by 132
“These findings constitute in vivo support for previous in vitro observations that (1) DC-HIL-L are expressed on activated (but not resting) T cells, (2) DC-HIL is a negative regulator of T-cell activation, and (3) soluble DC-HIL enhances T-cell–mediated responses.”
ICOS Ligation Recruits the p50α PI3K Regulatory Subunit to the Immunological Synapse
Fos, C., Salles, A., Lang, V., Carrette, F., Audebert, S., Pastor, S., Ghiotto, M., Olive, D., Bismuth, G., & Nunès, J. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1969 · Cited by 127
“This is in contrast to CD28 that has several Src homology 2 domain (SH2)4 (4) and SH3 binding motifs for proteins such as Grb2, GRID, Lck, Itk, and Tec (16).”
BackgroundInfluentialOrchestrating immune check-point blockade for cancer immunotherapy in combinations
Perez‐Gracia, J. L., Labiano, S., Rodriguez-Ruiz, M. E., Sanmamed, M. F., & Melero, I. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.002 · Cited by 138
“The exemplary co-stimulatory molecule on T cells is CD28, which upon ligation to CD80 (B7-1) or CD86 (B7-2) on antigen presenting cells provides key co-mitogenic, and antiapoptotic signals [2].”
Organization of proximal signal initiation at the TCR:CD3 complex
Guy, C. S., & Vignali, D. A. A. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00843.x · Cited by 130
“CD28 has been shown to influence multiple parameters of TCR-induced signaling, including those which are both proximal as well as distal to TCR crosslinking (96).”
BackgroundJindra, P. T., Bagley, J., Godwin, J. G., & Iacomini, J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000793 · Cited by 127
“The CD28 costimulatory pathway plays a central role in activating signaling pathways, such as the PI3K pathway, that promote T cell survival, cytokine production, and differentiation (1).”
BackgroundNF-κB inducing kinase: A key regulator in the immune system and in cancer
Thu, Y. M., & Richmond, A. J. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.06.002 · Cited by 146
“The signaling through TCR and CD28 are thought to cooperate for optimal activation of T cells and cytokine production [83].”
Kim, H. S., Das, A., Gross, C. C., Bryceson, Y. T., & Long, E. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.02.004 · Cited by 124
Fine Tuning and Efficient T Cell Activation with Stimulatory aCD3 Nanoarrays
Matić, J. D., Deeg, J., Scheffold, A., Goldstein, I., & Spatz, J. P. (2013) · Nano Letters · doi:10.1021/nl4022623 · Cited by 134
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
“Upon binding to B7-1 and B7-2 on antigen-presenting cells (APCs), CD28 trans-activates TCR signaling and thus improves antitumor response when antigen recognition occurs (50).”
BackgroundThe NKG2D receptor: sensing stressed cells
López‐Larrea, C., Suárez-Álvarez, B., López‐Soto, A., López‐Vázquez, A., & Gonzalez, S. R. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.004 · Cited by 128
CD4+CD28null T cells in coronary artery disease: when helpers become killers
Dumitriu, I. E., Araguas, E. T., Baboonian, C., & Kaski, J. C. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvn248 · Cited by 126
T-cell defects in patients with ARPC1B germline mutations account for combined immunodeficiency
Brigida, I., Zoccolillo, M., Cicalese, M. P., Pfajfer, L., Barzaghi, F., Scala, S., Oleaga-Quintas, C., Álvarez-Álvarez, J. A., Sereni, L., Giannelli, S., et al. (2018) · Blood · doi:10.1182/blood-2018-07-863431 · Cited by 119
Dual T cell– and B cell–intrinsic deficiency in humans with biallelic RLTPR mutations
Wang, Y., Ma, C. S., Ling, Y., Bousfiha, A., Camcioglu, Y., Jacquot, S., Payne, K., Crestani, E., Roncagalli, R., Belkadi, A., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160576 · Cited by 121
“Mice homozygous for the L432P substitution in Rltpr (Rltpr) resemble immunologically those lacking CD28 (Shahinian et al., 1993; Acuto and Michel, 2003).”
BackgroundBartolo, V. D., Montagne, B., Salek, M., Jungwirth, B., Carrette, F., Fourtane, J., Sol-Foulon, N., Michel, F., Schwartz, O., Lehmann, W. D., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062066 · Cited by 118
Self-citationGeneration and Growth of CD28nullCD8+ Memory T Cells Mediated by IL-15 and Its Induced Cytokines
Chiu, W. K., Fann, M., & Weng, N.-P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.7802 · Cited by 120
“In brief, RNA were extracted from cells by Stat 60 (Tel-Test) based on manufacturers’ protocol and quantified by Nanodrop (Nanodrop Technologies). cDNA synthesis was conducted using 1 g of total RNA with reverse transcriptase (SuperScript II; Invitrogen Life Technologies) based on manufacturer’s instructions. mRNA lev…”
BackgroundInfluentialPeperzak, V., Xiao, Y., Veraar, E. A. M., & Borst, J. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40178 · Cited by 115
Cutting Edge: Cbl-b: One of the Key Molecules Tuning CD28- and CTLA-4-Mediated T Cell Costimulation
Li, D., Gál, I., Vermes, C., Alegre, M.-L., Chong, A. S. F., Chen, L., Shao, Q., Adarichev, V., Xu, X., Koreny, T., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7135 · Cited by 117
“These data indicate that CTLA-4-B7 interactions potentiate TCR-induced Cbl-b re-expression, supporting the notion that CD28 and CTLA-4 quantitatively modify TCR signaling (4, 13, 33).”
BackgroundImmune system and sarcopenia: Presented relationship and future perspective
Zhang, X., Li, H., He, M., Wang, J., Wu, Y., & Li, Y. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.111823 · Cited by 123
Zygmunt, B. M., & Veldhoen, M. (2011) · Advances in immunology · doi:10.1016/b978-0-12-387664-5.00005-4 · Cited by 146
“Their expression is substantially increased upon PRR engagement, thereby licensing the activation of naive T cells (Acuto and Michel, 2003).”
BackgroundDumitriu, I. E., Baruah, P., Finlayson, C. J., Loftus, I. M., Antunes, R. F., Lim, P., Bunce, N., & Carlos Kaski, J. (2012) · Circulation Research · doi:10.1161/circresaha.111.261933 · Cited by 115
Syndecan-4 Mediates the Coinhibitory Function of DC-HIL on T Cell Activation
Chung, J.-S., Dougherty, I., Cruz, P. D., & Ariizumi, K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5778 · Cited by 114
“Costimulatory receptors include CD28 and ICOS on T cells (2), and their respective receptors (CD80/B7-1 and CD86/B7-2, and ICOS ligand) on APC (3).”
BackgroundThe life (and death) of CD 4 + CD 28 null T cells in inflammatory diseases
Dumitriu, I. E. (2015) · Immunology · doi:10.1111/imm.12506 · Cited by 118
Kalia, V., Penny, L. A., Yuzefpolskiy, Y., Baumann, F. M., & Sarkar, S. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.023 · Cited by 126
Metadata
- Authors
- Acuto, O., & Michel, F.
- Affiliations
- Institut Pasteur (FR)
- Corresponding author
- Acuto, Oreste
- ORCID
- Michel, Frédérique
- Venue
- Nature Reviews Immunology
- Published
- 2003-12
- Volume
- 3
- Issue
- 12
- Pages
- 939-951
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2055248228
- Cited by
- 775
- References
- 157
- Citations by year
- 2026: 26 · 2025: 32 · 2024: 31 · 2023: 23 · 2022: 42 · 2021: 33 · 2020: 32 · 2019: 25 · 2018: 38 · 2017: 43 · 2016: 42 · 2015: 35 · 2014: 29 · 2013: 37 · 2012: 33
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Association pour la Recherche sur le Cancer
- Centre National de la Recherche Scientifique
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD28, costimulation, T cell receptor signaling, T cell activation, naive T cells, clonal expansion, costimulatory receptors, signal amplification
- MeSH terms
- Animals, Carrier Proteins, Cell Cycle, Humans, Lymphocyte Activation, Membrane Proteins, Phosphoproteins, T-Lymphocytes, Signal Transduction, CD28 Antigens, Phosphatidylinositol 3-Kinases, Adaptor Proteins, Signal Transducing, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.